Xencor, Inc.
XNCRHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeXencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. Valued at $1.87B, XNCR is a small-cap name in its sector. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Market Cap
$1.87B
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
-7.08
EPS (TTM)
$-2.16
EPS (Fwd)
$-3.56
ROE
-29.1%
ROA
-16.8%
Cash
$456.5M
Total Debt
$170.1M
Free CF
-$94.5M
52W Change
76.4%
Annual Financials
Cash vs Debt
Where XNCR stands vs its 150-day and 200-day moving averages
As of the September 28, 2026 close, XNCR finished 45.92% above its 150-day moving average ($16.31) and 51.79% above its 200-day moving average ($15.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XNCR overbought or oversold?
At the September 28, 2026 close, XNCR's RSI(14) was 27.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $456.5M in cash comfortably exceeding the $170.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$94.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -29.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $275.1M to $125.6M.
With cash comfortably exceeding debt, XNCR has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Xencor, Inc. and its sector.